Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
Cogent Biosciences, Inc.
Study ID
NCT02776813
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • ACTR087 — BIOLOGICAL
  • rituximab — BIOLOGICAL

Study Details

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and efficacy of an autologous T-cell product expressing ACTR in combination with rituximab in subjects with refractory or relapsed CD20+ B-cell lymphoma.

Key Dates

Start date
Aug 31, 2016
Status verified
Mar 2020
Primary completion
Feb 12, 2020
Completion
Feb 12, 2020

Study Design

Enrollment
34 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ACTR087, in combination with rituximab

Primary Outcome Measure

Safety as assessed by dose limiting toxicities (DLTs) [ Time Frame: 28 days ]

Locations (7)

FacilityCityStateZIPSite coordinators
Banner MD Anderson Cancer CenterGilbertArizona85234-
Yale UniversityNew HavenConnecticut06520-
Loyola University ChicagoMaywoodIllinois60153-
Indiana Bone and Marrow TransplantationIndianapolisIndiana46237-
Massachusetts General HospitalBostonMassachusetts02114-
Duke University Medical CenterDurhamNorth Carolina27710-
Ohio State UniversityColumbusOhio43210-

Find similar trials in Gilbert, AZ

By research site
Banner MD Anderson Cancer Center· Gilbert, AZYale University· New Haven, CTLoyola University Chicago· Maywood, ILIndiana Bone and Marrow Transplantation· Indianapolis, INMassachusetts General Hospital· Boston, MADuke University Medical Center· Durham, NC

Related Studies